Juun 2022: Daraasad yar oo lagu sameeyay bukaannada kansarka malawadka ayaa keenay natiijooyin aan caadi ahayn: 100 boqolkiiba shakhsiyaadka ayaa ku jiray cafis. Natiijooyinka waxaa lagu daabacay Wargeyska Caafimaadka ee New England todobaadkan.
Tijaabada waxaa maalgelisay GlaxoSmithKline, oo soo saartay daawada dostarlimab, sida laga soo xigtay New York Times. Muddo lix bilood ah, bukaanada ku jira tijaabada ayaa la siiyay dostarlimab, an immunotherapy daawo kicinaysa habdhiska difaaca bukaanka si ay u beegsato xumaantooda.
According to the study, all 12 people had comparable mutations in mismatch repair-deficient kansarka mindhicirka, which occurs in roughly 5 to 10% of colorectal malignancies. Standard chemotherapy has a dismal prognosis for these malignancies.
"Waxay la'yihiin hidde-side u oggolaanaya inay hagaajiyaan DNA-da," dhakhtar Andrea Cercek, oo ah qoraaga daraasadda oo ka socda Xarunta Cudurrada Memorial Sloan Kettering, ayaa u sheegay CNN. "Natiijo ahaan, waxay leeyihiin isbeddello badan oo badan, iyo habka difaaca jirku wuxuu u ogaadaa kansarka shisheeye." "Marka aan maamulno immunotherapy, sida dostarlimab, waxaan runtii dib u soo nooleyneynaa habka difaaca si ay u aragto kansarka oo u disho."
Dostarlimab waa antibody kaas oo bartilmaameedsada borotiinka PD-1, kaas oo u taagan dhimashada unugyada barnaamijka 1. PD-1 waa borotiin laga helo dusha sare ee unugyada difaaca jirka ee T-unugyada kaas oo ka caawiya jidhku inuu aqoonsado oo burburiyo unugyada kansarka. Unugyada kansarku waxay markaa abuuri karaan kiimikooyin carqaladeeya PD-1, taasoo u oggolaanaysa inay dhaafaan ogaanshaha habka difaaca jirka. Dostarlimab waxay u shaqeysaa iyada oo ka hortagaysa unugyada kansarka inay ka baxsadaan nidaamka difaaca, u oggolaanaya habka difaaca inuu ogaado oo uu dilo unugyada kansarka. Cilmi-baadhayaashu waxay rabeen inay la socdaan daaweynta dostarlimab ee daaweynta kemoradiotherapy caadiga ah iyo qalliin, laakiin bukaannadu uma baahna. Sida laga soo xigtay daraasadda, dhammaan maadooyinka 12 ee dhammeeyey daaweynta dostarlimab oo lahaa dabagal 6-bilood ah ma aysan helin unugyada kansarka ama saameynaha waaweyn. Marka loo eego bayaan, wax kiisas ah oo horumar ah ama soo noqnoqonaya lama arag xitaa 25 bilood ka dib.
dhaqanka kansarka mindhicirka therapies can have life-changing consequences, according to Hanna Sanoff of the University of North Carolina’s Lineberger Comprehensive Cancer Center, who was not involved in the study but wrote an editorial about it.
"Labada qalliinka iyo shucaaca labaduba waxay leeyihiin saameyn muddo dheer ah bacriminta, caafimaadka galmada, iyo shaqada mindhicirka iyo kaadiheysta. "Cawaaqibka tayada noloshu waa mid muhiim ah, gaar ahaan haweenka awoodooda taranka ay waxyeelo u geysan doonto daaweynta hadda jirta," Cercek ayaa ku tiri bayaanka. "Iyada oo ay sii kordhayaan dhacdooyinka kansarka malawadka ee dhalinyarada, habkani wuxuu yeelan karaa saameyn weyn."
Khubarada ayaa ka digaya in tijaabadu ay xadidan tahay, ayna goor hore tahay in la sheego in bukaannadu ay ku sii jiri doonaan cafis. Sanoff wuxuu ku darayaa tifaftirka in xitaa shakhsiyaadka helay jawaab celin dhamaystiran shucaaca iyo kiimoterabiga ay la kulmi karaan soo noqoshada kansarka 20 ilaa 30 boqolkiiba kiisaska marka xumaanta loo maareeyo si aan loo baahnayn.
PD-1 waxay ku lug leedahay hannaan bayooloji oo weyn oo loo yaqaan "ka-hortagga isbaarada," kaas oo u shaqeeya sida damida ama daminta unugyada difaaca. Mid ka mid ah meelaha ugu firfircoon ee daraasadda oncology hadda waa bartilmaameedka PD-1 iyo qaybaha kale ee ka hortagga isbaarada ee daaweynta kansarka.
"Natiijooyinkani waxay sabab u yihiin yididiilo aad u weyn," Sanoff ayaa yidhi, "laakiin habkan oo kale weli kama beddeli karo habka daawaynta ee jira." Cilmi-baarista waa in la soo koobaa, ayuu raaciyay.
Waxay u sheegtay NPR, "Waxa aan runtii jeclaan lahaa inaan sameyno waa inaan helno tijaabo ballaaran oo dawadan looga faa'iidaysto dad aad u kala duwan si loo ogaado waxa dhabta ah, heerka jawaabta dhabta ah uu noqon doono." "Ma noqon doonto boqolkiiba boqol." Waxaan rajeynayaa inaan mustaqbalka awood u yeelan doono inaan carrabka ku qabto taas, laakiin waan ka shaki qabaa. Oo markaan aragno heerka jawaabta dhabta ah, waxaan aaminsanahay inaan awood u yeelan doono inaan tan si joogto ah u samayno."
